Integrated Diagnostics is developing large-scale, blood-based molecular diagnostics that detect important diseases like lung cancer and Alzheimer's at their earliest stages by simultaneously monitoring tens to hundreds of disease markers. The company, founded in October 2009 by systems biology pioneer Dr. Lee Hood, is creating a new generation of personalized medical solutions using sophisticated informatics for biomarker selection and a novel class of synthetically created diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents (PCCs). Integrated Diagnostics' mission is to build a new generation of low-cost, large-scale diagnostic assays for early detection of serious diseases. The company is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners, The Wellcome Trust, and BioTechCube Luxembourg. Foundational intellectual property is exclusively licensed from the Institute of Systems Biology and Caltech.

Key Contact